Merck (MRK)
Health Care · Pharma & Biotech · USA
$149.54
+2.21%
About
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Source: Yahoo Finance
Sector
Healthcare
Website
www.merck.comIndex Benchmarks
| Period | MRK | Dow Jones | Nasdaq | S&P 500 |
|---|---|---|---|---|
| 1D | +2.18% | -1.09%(+3.3) | -2.86%(+5.0) | -1.82%(+4.0) |
| 1W | +2.93% | -0.85%(+3.8) | -2.00%(+4.9) | -0.57%(+3.5) |
| 1M | +3.97% | +1.66%(+2.3) | -5.34%(+9.3) | -1.13%(+5.1) |
| YTD | +40.46% | +7.00%(+33.5) | +9.47%(+31.0) | +10.52%(+29.9) |
| 1Y | +73.90% | +8.85%(+65.1) | +7.22%(+66.7) | +10.82%(+63.1) |
Numbers in parentheses show out/underperformance vs the index
Previous Close$146.33
Open$149.55
Day's Range$147.43 - $151.35
52 Week Range$82.01 - $156.92
Volume12.30M
Avg. Volume10.36M
Market Cap$369B
Beta (5Y)0.22
P/E Ratio150.4x
EPS$0.99
P/B Ratio8.80x
Dividend Yield2.27%
Revenue$67B
Net Income$2.5B
Operating Margin9.2%
Total Debt$54B
Cash$7.1B
1y Target Est$159.87